Clinical trial
A Randomized, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of Once Weekly Subcutaneous Injections of Pemziviptadil (PB1046), a Sustained-Release VIP (Vasoactive Intestinal Peptide) ANalogue, in Hospitalized COVID-19 Patients at HiGh Risk for Rapid Clinical Deterioration and ARDS (PB1046 VANGARD Study)
NCT04433546 is registered in ClinicalTrials.gov with PhaseBio Pharmaceuticals Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of Once Weekly Subcutaneous Injections of Pemziviptadil (PB1046), a Sustained-Release VIP (Vasoactive Intestinal Peptide) ANalogue, in Hospitalized COVID-19 Patients at HiGh Risk for Rapid Clinical Deterioration and ARDS (PB1046 VANGARD Study)
- Lead sponsor
- PhaseBio Pharmaceuticals Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- July 15, 2020
- Completion date
- December 2, 2020
- Enrollment
- 54 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
acute respiratory distress syndrome, cardiac complication, cardiac dysfunction, cardiac event, cardiac failure, cardiac infarct, coronavirus, covid 19, cytokine storm, hypoxemic respiratory failure, hypoxic respiratory failure, pneumonia, pulmonary edema, pulmonary inflammation, respiratory complication, respiratory failure, respiratory insufficiency, sars-cov-2